In 1998, the Food and Drug Administration (FDA) approved the use of Trastuzumab in immunotherapy due to its potential inhibitory function to increase the overall survival in HER2-overexpressed metastatic cancers such as gastric and breast cancers [5,6,7]. This evidence concerns the gene ERBB2 and breast carcinoma.